Drugs.com - Clinical Trials

Johnson & Johnson’s Dual-Targeting CAR T-Cell Therapy Shows Encouraging First Results in Large B-Cell Lymphoma

MILAN (June 13, 2025) – Johnson & Johnson (NYSE: JNJ) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti-CD19/CD20 bispecific autologous chimeric...

Jun 14, 2025 - 01:40
 0
Johnson & Johnson’s Dual-Targeting CAR T-Cell Therapy Shows Encouraging First Results in Large B-Cell Lymphoma
MILAN (June 13, 2025) – Johnson & Johnson (NYSE: JNJ) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti-CD19/CD20 bispecific autologous chimeric...
Read More

Tags:

Previous Article

Tesla faces protests in Austin over Musk's robotaxi plans

Next Article

Merck Initiates Phase 3 Study Evaluating V181 Dengue Vaccine Candidate

Related Posts

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

ImmunityBio Receives FDA Expanded Access Authorization ...

Jun 3, 2025  0

Teva Celiac Disease Candidate TEV-53408 Granted Fast Track Designation by US FDA

Teva Celiac Disease Candidate TEV-53408 Granted Fast Tr...

May 30, 2025  0

Repurposing Blood Pressure Drug Reserpine May Prevent Vision Loss in Inherited Blinding Diseases

Repurposing Blood Pressure Drug Reserpine May Prevent V...

May 12, 2025  0